Literature DB >> 12586172

A novel nonsense mutation with a compound heterozygous mutation in TGFBI gene in lattice corneal dystrophy type I.

Tohru Sakimoto1, Hitoshi Kanno, Jun Shoji, Yoji Kashima, Shigeki Nakagawa, Shiro Miwa, Mitsuru Sawa.   

Abstract

PURPOSE: We examined transforming growth factor beta-induced (TGFBI) gene mutations in a family with lattice corneal dystrophy type I.
METHODS: The proband was one of the offspring of a consanguineous marriage; 4 affected and 3 unaffected individuals of the family were investigated. Genomic DNA of each case was extracted and used for polymerase chain reaction (PCR). The exon 4, 11, and 12 of the TGFBI gene were directly sequenced. The mutations were confirmed by PCR restriction fragment length polymorphism analysis.
RESULTS: There was no significant difference in phenotype between the proband and the other 2 patients, except for progression of the corneal opacity with age. R124C mutation was detected in all affected individuals. In addition, G470X, a novel nonsense mutation, was detected in the proband, resulting in the proband being a compound heterozygote with the TGFBI gene. Her unaffected daughter was found to be heterozygous for G470X.
CONCLUSION: It is most likely that the novel nonsense mutation is not pathogenic, and that the mutant keratoepithelin protein with R124C is responsible for the phenotype.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12586172     DOI: 10.1016/s0021-5155(02)00644-5

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  8 in total

1.  Novel and known mutations of TGFBI, their genotype-phenotype correlation and structural modeling in 3 Chinese families with lattice corneal dystrophy.

Authors:  Xingwu Zhong; Suqin Chen; Weijun Huang; Jun Yang; Xiaolian Chen; Yan Zhou; Qiang Zhou; Yiming Wang
Journal:  Mol Vis       Date:  2010-02-15       Impact factor: 2.367

2.  Different phenotypes of lattice corneal dystrophy type I in patients with 417C>T (R124C) and 1762A>G (H572R) mutations in TGFBI (BIGH3).

Authors:  Pablo Romero; Mauricio Moraga; Luisa Herrera
Journal:  Mol Vis       Date:  2010-08-13       Impact factor: 2.367

3.  Mutation-Independent Allele-Specific Editing by CRISPR-Cas9, a Novel Approach to Treat Autosomal Dominant Disease.

Authors:  Kathleen A Christie; Louise J Robertson; Caroline Conway; Kevin Blighe; Larry A DeDionisio; Connie Chao-Shern; Amanda M Kowalczyk; John Marshall; Doug Turnbull; M Andrew Nesbit; C B Tara Moore
Journal:  Mol Ther       Date:  2020-05-08       Impact factor: 11.454

4.  Mutation Analysis of the TGFBI Gene in Consecutive Korean Patients With Corneal Dystrophies.

Authors:  Ju Sun Song; Dong Hui Lim; Eui-Sang Chung; Tae-Young Chung; Chang-Seok Ki
Journal:  Ann Lab Med       Date:  2015-04-01       Impact factor: 3.464

5.  Compound heterozygous mutations in TGFBI cause a severe phenotype of granular corneal dystrophy type 2.

Authors:  Ikhyun Jun; Yong Woo Ji; Seung-Il Choi; Bo Ram Lee; Ji Sang Min; Eung Kweon Kim
Journal:  Sci Rep       Date:  2021-03-26       Impact factor: 4.379

6.  Anticipation in familial lattice corneal dystrophy type I with R124C mutation in the TGFBI (BIGH3) gene.

Authors:  Pablo Romero; Marlene Vogel; Jose-Manuel Diaz; Maria-Patricia Romero; Luisa Herrera
Journal:  Mol Vis       Date:  2008-05-07       Impact factor: 2.367

7.  A pathogenic variant in the transforming growth factor beta I (TGFBI) in four Iranian extended families segregating granular corneal dystrophy type II: A literature review.

Authors:  Aliasgar Mohammadi; Azam Ahmadi Shadmehri; Mahnaz Taghavi; Gholamhossein Yaghoobi; Mohammad Reza Pourreza; Mohammad Amin Tabatabaiefar
Journal:  Iran J Basic Med Sci       Date:  2020-08       Impact factor: 2.699

8.  TGF-β1 enhanced myocardial differentiation through inhibition of the Wnt/β-catenin pathway with rat BMSCs.

Authors:  Yang Lv; Xiu-Juan Li; Hai-Ping Wang; Bo Liu; Wei Chen; Lei Zhang
Journal:  Iran J Basic Med Sci       Date:  2020-08       Impact factor: 2.699

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.